Drugs Made in America Acquisition CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Drugs Made in America Acquisition Corp. reports Q1 2026 net income of $1.97 million, driven by trust account interest, while continuing its search for a business combination.
NASDAQ
Drugs Made In America Acquisition Corp. reports net income of $5.7 million for the nine months ended September 30, 2025, driven by trust account interest, but faces going concern doubts.
NASDAQ
Drugs Made In America Acquisition Corp., a blank check company, reported net income driven by trust account interest but faces a going concern warning and internal control weaknesses.
NASDAQ
Drugs Made In America Acquisition Corp. reports a net income of $1,254,543 for the quarter ended March 31, 2025, primarily due to interest earned on its trust account.